Aceto Announces Management Realignment

LAKE SUCCESS, N.Y., Oct. 21, 2009 (GLOBE NEWSWIRE) -- Aceto Corporation (Nasdaq:ACET - News), a global leader in the sourcing, quality assurance, regulatory support, marketing and distribution of chemically derived pharmaceuticals, biopharmaceuticals, specialty chemicals and crop protection products, today announced that Chairman and CEO Leonard S. Schwartz will be leaving the Company on November 20, 2009 after 40 years of service. The Company has separated the office of Chairman of the Board from that of Chief Executive Officer. President Vincent Miata will assume the responsibilities of Chief Executive Officer effective immediately. Mr. Miata has been with the Company for 30 years in a variety of executive positions, most recently assuming the office of President. The Board, on the recommendation of the Independent Directors, has included Vincent Miata's name on the slate of nominees for Director for the Company's December shareholders meeting. Mr. Miata will be responsible for the worldwide operations of the Company. Also effective immediately Albert Eilender, currently a Board member and the Lead Independent Director, has been named by the Board of Directors as the Non-Executive Chairman of the Aceto Board. Mr. Eilender has been on the Aceto Board since 2000 and has served as the Lead Independent Director of the Company since 2005. He has more than 30 years of diverse senior level experience in the specialty chemicals and pharmaceutical industries and has had direct financial responsibility ...
Click here to read the whole Article (external link)

Aceto Announces Fiscal 2010 First Quarter Results of Operations

LAKE SUCCESS, N.Y., Nov. 6, 2009 (GLOBE NEWSWIRE) -- Aceto Corporation (Nasdaq:ACET - News), a global leader in the sourcing, quality assurance, regulatory support, marketing and distribution of chemically derived pharmaceuticals, nutraceuticals, specialty chemicals and crop protection products, today announced results of operations for its fiscal 2010 first quarter ended September 30, 2009. Net sales for the fiscal 2010 first quarter were $70.6 million, a decrease of 24.8% from $93.8 million reported in the year ago quarter. Gross profit decreased 37.6% to $11.8 million in the 2010 fiscal quarter compared to $18.9 million in the 2009 quarter. SG&A expenses decreased 16.8% to $10.1 million in the 2010 quarter compared to $12.2 million in the year ago comparable quarter. Net income decreased 78% to $1.0 million, or $0.04 per diluted share, compared to $4.6 million or $0.18 per diluted share in the 2009 quarter. Albert Eilender, Non-Executive Chairman of Aceto stated, "This past year, as well as the first quarter of the current fiscal year, have been difficult periods for the Company, largely due to the fact that the global economy has contracted beyond what was anticipated a short 12 months ago. Clearly, we are not satisfied with the operating results we have reported for the first quarter of fiscal 2010. Be assured that even though we are confident that in time the general economy will noticeably improve, we are reevaluating how we allocate our efforts and financial resources as well as the steps we can ta...
Click here to read the whole Article (external link)

Aceto Corporation Schedules Fiscal 2010 First Quarter Financial Results News Release and Conference Call

Aceto Corporation Schedules Fiscal 2010 First Quarter Financial Results News Release and Conference Call - Yahoo! Finance.gnwlistitemmarginbottom {margin-bottom: 10.0px} .gnwtablebottommargin {margin-bottom: 10.0px} .gnwcellpaddingleft0 {padding-left: 0.0px} .gnwverticalaligntop {vertical-align: top} .gnwtextaligncenter {text-align: center} .gnwcellparagraphmargin {margin-bottom: 0px; margin-top: 0px} .gnwverticalalignbottom {vertical-align: bottom} .gnwwhitespacenowrap {white-space: nowrap} .gnwtextalignright {text-align: right} .gnwcellpaddingright0 {padding-right: 0.0px} .gnwunderlinestyle {text-decoration: underline} .gnwtextalignleft {text-align: left} .gnw_heading {font: 16px Arial; text-align: center} .gnw_subhead {font: 12px Arial; text-align: center} .gnw_colhead {font: 12px Arial; text-align: center} .gnw_colhead_uline {font: 12px Arial; text-align: center; border-bottom: solid black 1.0pt;} .gnw_colhead_dline {font: 12px Arial; text-align: center; border-bottom: double black 2.5pt;} .gnw_label {font: 12px Arial; vertical-align: bottom; text-align: left } .gnw_label_uline {font: 12px Arial; vertical-align: bottom; text-align: left; border-bottom: solid black 1.0pt;} .gnw_label_uline_i10 {font: 12px Arial; vertical-align: bottom; text-align: right; border-bottom: solid black 1.0pt;} .gnw_label_uline_i15 {font: 12px Arial; vertical-align: bottom; text-align: right; border-bottom: solid black 1.0pt;} .gnw_label_uline_i20 {font: 12px Arial; vertical-align: bottom; text-align: right; border-bottom: solid black 1.0pt;} .gnw_label_uline_i25 {font: 12px Arial; vertical-align: bottom; text-align: right; border-bottom: solid black 1.0pt;} .gnw_label_uline_i30 {font: 12px Arial; vertical-align: bottom; text-align: right; border-bottom: solid black 1.0pt;} .gnw_label_dline {font: 12px Arial; vertical-align: bottom; text-align: left; border-bottom: double black 2.5pt;} .gnw_label_i10 {font: 12px Arial; vertical-align: bottom; text-align: left; padding-left: 10.0px;} .gnw_label_i15 {font: 12px Arial; vertical-a...
Click here to read the whole Article (external link)

ACETO CORP Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhibits

Show all filings for ACETO CORP | Request a Trial to NEW EDGAR Online Pro Form 8-K for ACETO CORP 21-Oct-2009Change in Directors or Principal Officers, Financial Statements and Exhibits Copyright © 2009 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service - Copyright/IP Policy - Send Feedback SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All information provided "as is" for infor...
Click here to read the whole Article (external link)

Q1 2010 Aceto Earnings Release - Before Market Open

Earnings Announcements for Friday, November 6CompanySymbolTimeConferenceCallA.C. Moore Arts & CraftsACMRBefore Market OpenAARHUSKARLSHAMN ABARHUF.PK02:30 am ETAastrom BiosciencesASTMTime Not SuppliedACE Aviation Holdings, Inc.ACE-A.TOBefore Market OpenAcetoACETBefore Market OpenAchillion Pharmaceuticals Inc.ACHNBefore Market OpenADVANCED CARD SYSTEMS HLDGS8210.HKTime Not SuppliedAdvanced Info Service PLCAVIFY.PKTime Not SuppliedAerCap Holdings N.V.AERBefore Market OpenListenAES CorporationAESBefore Market OpenListenAffirmative Insurance Holdings Inc.AFFMTime Not SuppliedAIRCASTLE LTDAYRBefore Market OpenListenAllied Healthcare ProductsAHPITime Not SuppliedALLIED TECHNOLOGIES LTDA13.SIAfter Market CloseALPIQ HOLDING LTDALPQF.PK01:00 am ETAmerican International GroupAIGBefore Market OpenAMERICAN OIL & GAS I...
Click here to read the whole Article (external link)

Aceto Corporation Q1 2010 Earnings Call Transcript

Aceto Corporation (ACET) Q1 2010 Earnings Call November 6, 2009 10:00 am ET Executives Ted Ayvas – Director Investor Relations Vincent Miata – President Albert Eilender – Non Executive Chairman of the Board Douglas Roth – Chief Executive Officer Analysts Daniel Rizzo – Sidoti & Company Kevin McCanine – Main Line Capital [Lester Petrezzi – Private Investor] [Alan Brotstchein – AB Analytical Services] Roland Philini – Southpaw Investments] Eugene Fox – Cardinal Capital Management Presentation Operator Welcome to the Aceto Corporation’s fiscal 2010 first quarter financial results finance release and conference call. This conference call may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1033 as amended and Section 21E of the Securities Exchange Act of 1934 as amended. These forward-looking statements are based on current expectations, estimates and projections of management. Aceto intends for these forward-looking statements to be covered by the Safe Harbor Provisions for the forward-looking statements. Words such as anticipate, expect, intend, plans, beliefs, seeks, estimates or variations of such words are intended to identify such forward-looking statements. The forward-looking statements contained in this conference call include but are not limited to statements regarding the improvement of the general economy, the future progress of our initiatives, viability of finished dosage from generic drugs as a long term business opportunity, our ability to capitalize on the generic protection market growth and our ability to use financial strength to take advantage of future business opport...
Click here to read the whole Article (external link)

Biosimilars, Biologics, Biotech And Specialty Pharmaceuticals: Piper Jaffray Picks The Stocks And Sectors With Highest Potential Returns For Investors

67 WALL STREET, New York - November 6, 2009 - The Wall Street Transcript has just published its Pharmaceuticals Report offering a timely review of the sector to serious investors and industry executives. This 76 page feature contains expert industry commentary through in-depth interviews with public company CEOs, Equity Analysts and Money Managers. The full issue is available by calling (212) 952-7433 or via The Wall Street Transcript Online. Topics covered: Small-Cap Specialty Pharma - Patent Expiration - Pending Health Care Reform - Cultivating And Expanding R&D Pipelines - Chinese Drug Manufacturers - Brisk M&A Activity - Indian Pharma VS. U.S. Pharma - Competition From Generics - FDA Approval Process - Clinical Research Outsourcing Market - Stem Cell-Based Technology - Cancer Radiation Therapy - Expansion Into Asian Markets - Traditional Chinese Medicine VS. Western Medicine In Chinese Pharma Companies include: Aeolus Pharmaceuticals (AOLS.OB); Nutra Pharma (NPHC.OB); Quick-Med Technologies (QMDT.OB); Abbott Labs (ABT); Alexza Pharmaceuticals (ALXA); AmexDrug Corporation (AXRX.OB); Aurobindo Pharma (AUROBINDOP.BO); BioClinica (BIOC); BioPharm Asia (BFAR.OB); Biocon (BIOCON.BO); Cephalon (CEPH); China Sky One Medical, Inc. (CSKI); Claris Lifesciences (CLARICH.BO); Cortex Pharmaceuticals (COR); Daiichi Sankyo (DSKYF.PK); Dr.Reddy's (RDY); Elan (Elan); Eli Lilly (LLY); Forest (FRX); GeoPharma (GORX); Glaxo (GSK); Glenmark (GLENMARK.BO); Johnson & Johnson (JNJ); Lupin (LUPINSL.BO); Mannatech (MTEX); Matrix Laboratories (ATRIXLAB.BO); Medical Nutrition (MDNU); Merck KGaA (MKGAY.PK); Mylan (MYL); Ne...
Click here to read the whole Article (external link)

ACETO CORP Files SEC form 8-K, Results of Operations and Financial Condition

Show all filings for ACETO CORP | Request a Trial to NEW EDGAR Online Pro Form 8-K for ACETO CORP 6-Nov-2009Results of Operations and Financial Condition Copyright © 2009 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service - Copyright/IP Policy - Send Feedback SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All information provided "as is" for informational purposes only, not intended...
Click here to read the whole Article (external link)

ACETO CORP Financials

PERIOD ENDING30-Sep-0930-Jun-0931-Mar-0931-Dec-08Total Revenue70,609  74,792  79,800  74,215  Cost of Revenue58,793  63,109  66,545  62,470  Gross Profit11,816  11,683  13,255  11,745  Operating ExpensesResearch Development -   -   -  (118)Selling General and Administrative10,140  10,653  10,458  10,549  Non Recurring -   -   -   -  Others -   -   -   -  Total Operating Expenses -   -   -   -  Operating Income or Loss1,676  1,030  2,797  1,314  Income from Continuing OperationsTotal Other Income/Expenses Net8  472  (263)359  Earnings Before Interest And Taxes1,684  1,502  2,534  1,673  Interest Expense51  31  5  53  Income Before Tax1,633  1,471  2,529  1,620  Income Tax Expense630  420  594  528  Minority Interest -   -   -   -  Net Income From Continuing Ops1,003  1,051  1,935  1,092  Non-recurring EventsDiscontinued Operations -   -   -   -  Extraordinary Items -   -   -   -  Effect Of A...
Click here to read the whole Article (external link)